Denmark-based Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ozempic (once-weekly semaglutide) for the treatment of peripheral artery disease (PAD).
Clinical Trial Results
The recommendation is supported by positive results from the Phase IIIb STRIDE study, which involved 792 symptomatic patients with type 2 diabetes and PAD. The study assessed the impact of semaglutide on patients’ physical function, particularly leg pain during walking.
Key Findings
At week 52, semaglutide demonstrated a 13% improvement in maximum walking distance compared to placebo. Additionally, patients on semaglutide showed a 39.9-meter treatment difference on steep (12%) inclines.-Fineline Info & Tech
